AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Tumor necrosis factor receptor superfamily member 6

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries for receptors.

 Fig. 1. The sreening workflow of Receptor.AI

The method involves detailed molecular simulations of the receptor in its native membrane environment, with ensemble virtual screening focusing on its conformational mobility. When dealing with dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets on and between the subunits are established to address all possible mechanisms of action.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P25445

UPID:

TNR6_HUMAN

Alternative names:

Apo-1 antigen; Apoptosis-mediating surface antigen FAS; FASLG receptor

Alternative UPACC:

P25445; A9UJX4; B6VNV4; Q14292; Q14293; Q14294; Q14295; Q16652; Q5T9P1; Q5T9P2; Q5T9P3; Q6SSE9

Background:

Tumor necrosis factor receptor superfamily member 6, also known as FAS, plays a pivotal role in regulating programmed cell death and maintaining immune system homeostasis. It acts as a receptor for TNFSF6/FASLG, initiating apoptosis through the recruitment of FADD and caspase-8. This process is crucial for peripheral tolerance and the antigen-stimulated suicide of mature T-cells.

Therapeutic significance:

Autoimmune lymphoproliferative syndrome 1A, a disorder linked to FAS gene variants, highlights the protein's critical role in immune regulation. Understanding FAS's mechanisms offers a pathway to novel treatments for autoimmune diseases and immune system disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.